In patients with multiple myeloma, combined vincristine, doxorubicin and dexamethasone (VAD) is the most frequently used induction therapy before autologous stem-cell transplantation (ASCT ...

Corticosteroid therapy must be tapered because of its interactions with the hypothalamic-pituitary-adrenocortical (HPA) axis. The hypothalamus secretes corticotropin releasing factor, which acts ...

For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not negatively impact survival, according to a study published online Jan. 2 in Blood.

The usual but empirical initial dose in brain tumor patients is an intravenous bolus of 10 mg of dexamethasone, followed by a maintenance dose of 4 mg given by the intravenous (IV) route every 6 ...

It is also the first phase III study to evaluate the SC administration of a cancer drug via an OBDS ... with Bristol Myers’ Pomalyst and dexamethasone, is approved to treat adult patients ...